Commercializing Flow Chemistry Summit

Memo

The inaugural Commercializing Flow Chemistry Summit is your catalyst to bridge the gap between using flow for a single step in R and D to supporting fully integrated GMP drug substance manufacturing, from technical, economic and regulatory standpoints. Over the last few years, we have witnessed proven case studies from the likes of GSK, AbbVie, Bristol-Myers Squibb to employ flow chemistry in both drug discovery and development. With the benefits made possible by this technology, the flow chemistry market revenue is now expected to hit US$2.5 billion by 2026. The CFC Summit will focus on continuous flow applications in both drug discovery and commercial manufacturing within pharma and biotech, from enabling drug discovery, improving safety profiles to easing of scale-up. With these benefits truly beginning to be realized in a commercial environment and by regulatory bodies, we are at a tipping point for the widespread adoption of flow chemistry in pharma and biotech. This 3-days summit will be your unique platform this summer, whether you’re looking to join the movement or stay ahead of the curve. Prices:Conference Only - Primary: GBP 999.0Conference Only - Solution Providers : GBP 2449.0 Speakers: Flavien Susanne, Head of Product Development, SiSaf Ltd., C. Oliver Kappe, Professor of Chemistry, University of Graz, Sebastian Härtner, Associate Director, Future Manufacturing EMD Performance Materials, Kaid Harper, Senior Scientist, AbbVie, David Emiabata, Smith Scientific Fellow II, Vertex Pharmaceuticals, Pierre Boulas, Senior Director, Head of Pharmaceutical Development; Chair Emeritus, Biogen; IQ Consortium, Alexander O’Brien, Process Chemist, GSK, David Harris, Head PreDevelopment Sciences and Head Waltham Site, Sanofi, Kevin Cole, Principal Research Scientist, Eli Lilly and Company, Luke Webster, Associate Consultant Engineer, Eli Lilly and Company, Alastair Florence Director, Director EPSRC Future Continuous Manufacturing and Advanced Crystallisation Hub (CMAC), University of Strathclyde, Matt Bio, President and CEO, Snapdragon Chemistry, David Thompson, Professor of Organic Chemistry ; Co-Founder, Purdue University ; Continuity Pharma, Aaron Beeler, Associate Professor of Chemistry, Boston University, Jason Williams, Senior Scientist, Research Center Pharmaceutical Engineering GmbH, Atul Dubey, Director of Pharmaceutical Continuous Manufacturing (PCM), USP, Malcolm Berry, Founder, MB Chemistry Consulting Ltd, Paul Hermant, Process Analytical Technology Manager, CONTINUUS Pharmaceuticals, Inc. Time: 8:00 am - 5:00 pm